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Response
CEBPA promoter hypermethylation in a subset of myeloid/T-lymphoid leukemias with a
distinct gene expression profile
With great interest we have read the letter by Terriou and
coworkers, who have performed an extensive survey of CEBPA
CpG promoter hypermethylation in T-ALL as well as in a selection
of immature acute myeloid leukemia (AML) cases. This study
relates to our previous work in which we identified hypermethyl-
ation of the proximal CEBPA promoter in a small subset of AMLs
with low CEBPA mRNA.1 It should be noted that the patient group
we described was not primarily defined by CEBPA promoter
hypermethylation. Instead, those cases were studied because they
exhibited a unique gene expression profile. In addition to this most
discriminating feature, the leukemic blasts coexpressed CD34 and
T-cell antigens with myeloid markers, frequently carried NOTCH1
mutations, and expressed the transforming gene TRIB2.1,2 Using a
predictive gene expression signature in an independent cohort of
AML, we identified genetically and immunophenotypically similar
cases with silenced CEBPA.
In the present study, Terriou et al found CEBPA promoter
hypermethylation in 4/54 AML cases. These 4 cases all revealed
one or more T-cell characteristics (cCD3, CD7, and/or TCRG
rearrangement) and may therefore resemble the leukemias we
described. In T-ALL, the investigators found CEBPA promoter
hypermethylation more frequently, in 37/99 cases. Importantly,
however, only a minority of those T-ALLs with methylated CEBPA
coexpressed myeloid surface markers (CD13 and/or CD33) and
CD34. The findings of Terriou et al therefore indicate that CEBPA
proximal promoter hypermethylation in combination with an
immature myeloid/T-lymphoid immunophenotype is generally rare
in acute leukemia, and can be found in a small percentage of AML
as well as in a small fraction of T-ALL. It will be important to apply
gene expression profiling to these cases to fully assess their
relationship with the leukemias that we described previously.
Together, these observations highlight the challenges in classify-
ing particular acute leukemias as AML, ALL, or a unique entity. We
believe that studies as the one performed by Terriou et al will be
instrumental in obtaining a better understanding of this topic. Gene
expression profiling applied to these AML and T-ALL cohorts will
clearly be of added value. Combining data from multiple research
groups will be a requirement to address important questions
regarding prognosis, and should help to evaluate according to
which protocols these relatively small patient groups are best
treated.
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To the editor:
JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with
donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell
transplantation
Primary myelofibrosis is a myeloproliferative disease, and results
of conventional treatment remain unsatisfactory.1,2 Allogeneic stem
cell transplantation after dose-reduced conditioning has become a
reasonable, curative treatment option.3,4 Single case reports about
successful donor lymphocyte infusion (DLI) for relapsed patients
provided evidence of a graft-versus-myelofibrosis effect.5-7 Here,
we report on 17 patients with either myelofibrosis (n  16) or
secondary AML post myelofibrosis (n  1) and a median age of
52 years (range, 32-63 years) who received DLI from related
(n  5) or unrelated (n  12) donor, either for clinical relapse
(salvage DLI; n  9) or residual disease monitored by JAK2
mutation level in peripheral blood (preemptive DLI; n  8).
Details are summarized in Table 1. One patient (no. 9) received
DLI twice: once for molecular residual disease and once for
reappearance of molecular disease. Sixteen patients were JAK2-
V617F–positive. The median time from transplantation to first DLI
was 269 days (range, 127-1570 days). The median percentage of
JAK2V617 mutation level in peripheral blood before first DLI was
6.2% (range, 0.2%-72.8%) and significantly higher in patients with
clinical relapse than with molecular relapse (24.7% vs 0.37%;
P  .03). The median cell dose of the first DLI was 106 CD3 cells
per kilogram of body weight (BW; range, 0.5-9  106 cells/
kg BW). Two patients received as first DLI CD4-selected T cells
(5  106 CD4 cells/kg BW). Second and subsequent half-log–
increased DLI were given if no graft-versus-host disease (GVHD)
and no significant response were observed. The median interval
between the first and the second DLI was 103 days (range,
43-661 days). The response to DLI for relapsed patients was
determined by the response criteria of the International Working
Group,8 and for residual disease by quantitative real time JAK2-
V617F polymerase chain reaction (PCR) performed from genomic
DNA from peripheral blood as recently described.9 The sensitivity
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